Aggressive multiple sclerosis: proposed definition and treatment algorithm

Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple Sclerosis

(2015) Richard K. Burt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial

(2015) G. L. Mancardi et al.   NEUROLOGY

High-Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS)

(2015) Richard A. Nash et al.   JAMA Neurology

Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

(2014) Jorge Correale et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

(2014) Thomas P Leist et al.   LANCET NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Disease Activity Free Status

(2014) Carolyn J. Bevan et al.   JAMA Neurology

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

(2013) Victor M Rivera et al.   BMC Neurology

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

(2013) Gilles Edan et al.   CNS DRUGS

Autologous Hematopoietic Stem Cell Transplantation as a Treatment Option for Aggressive Multiple Sclerosis

(2013) Nikolai Pfender et al.   Current Treatment Options in Neurology

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS

(2013) Jeffrey A. Cohen et al.   JOURNAL OF NEUROLOGY

Characterising aggressive multiple sclerosis

(2013) Suresh Menon et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment

(2012) Joachim B. Havla   ARCHIVES OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper

(2012) R Saccardi et al.   Multiple Sclerosis Journal

Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases

(2012) Bahia Hakiki et al.   Multiple Sclerosis Journal

Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned

(2012) Harold L. Atkins et al.   Neurotherapeutics

Alemtuzumab Therapy for Multiple Sclerosis

(2012) Alasdair J. Coles   Neurotherapeutics

Treatment of multiple sclerosis with Anti-CD20 antibodies

(2011) Barbara Barun et al.   CLINICAL IMMUNOLOGY

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

(2011) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Demographic and clinical characteristics of malignant multiple sclerosis

(2011) T. Gholipour et al.   NEUROLOGY

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

(2011) P. W. O'Connor et al.   NEUROLOGY

Natalizumab drug holiday in multiple sclerosis: Poorly Tolerated

(2010) Joep Killestein et al.   ANNALS OF NEUROLOGY

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis

(2010) C. Lukas et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later

(2010) Thomas F. Scott et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

(2010) Christoph Heesen et al.   Multiple Sclerosis Journal

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

(2010) Gavin Giovannoni et al.   NEW ENGLAND JOURNAL OF MEDICINE

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

High-Dose Cyclophosphamide in the Treatment of Multiple Sclerosis

(2009) Robert Jay Schwartzman et al.   CNS Neuroscience & Therapeutics

One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis

(2009) L. Prosperini et al.   EUROPEAN JOURNAL OF NEUROLOGY

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

(2009) M. Hutchinson et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis patients—benefit-risk preferences: Serious adverse event risks versus treatment efficacy

(2009) F. Reed Johnson et al.   JOURNAL OF NEUROLOGY

Concepts of induction and escalation therapy in multiple sclerosis

(2009) Peter Rieckmann   JOURNAL OF THE NEUROLOGICAL SCIENCES

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

(2009) Richard K Burt et al.   LANCET NEUROLOGY

Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis

(2008) Chitra Krishnan et al.   ARCHIVES OF NEUROLOGY

Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis

(2008) L. K. Fisniku et al.   BRAIN

Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus

(2008) Ines C. Kanter et al.   EPILEPSIA

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

(2008) Gianluigi Mancardi et al.   LANCET NEUROLOGY

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Relationship between MRI lesion activity and response to IFN-β in relapsing–remitting multiple sclerosis patients

(2008) J Río et al.   Multiple Sclerosis Journal

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

(2008) E Cocco et al.   Multiple Sclerosis Journal

Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis

(2008) Christine Lebrun et al.   Multiple Sclerosis Journal

Induction vs. escalation of therapy for relapsing Multiple Sclerosis: the evidence

(2008) Mark S. Freedman   NEUROLOGICAL SCIENCES

Induction vs. escalating therapy in Multiple Sclerosis: practical implications

(2008) Giancarlo Comi   NEUROLOGICAL SCIENCES

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

(2007) E. Le Page et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY